ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
ChromaDex Corp. (NASDAQ:CDXC), a leader in NAD+ research and healthy aging, has announced its Q2 2024 financial results conference call. The call is scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET. Financial results will be released via press release after market close on the same day. Investors can join the call using the toll-free number 1-888-596-4144 (Conference ID: 8584242) or via webcast. Management will discuss Q2 results and provide a general business update. A replay will be available until August 14, 2024. This event offers investors an opportunity to gain insights into ChromaDex's financial performance and future outlook.
ChromaDex Corp. (NASDAQ:CDXC), un leader nella ricerca su NAD+ e in invecchiamento sano, ha annunciato la sua call per i risultati finanziari del Q2 2024. La chiamata è programmata per mercoledì 7 agosto 2024, alle 16:30 ET. I risultati finanziari saranno resi noti tramite comunicato stampa dopo la chiusura del mercato lo stesso giorno. Gli investitori possono unirsi alla chiamata utilizzando il numero verde 1-888-596-4144 (ID Conferenza: 8584242) o tramite webcast. La direzione discuterà i risultati del Q2 e fornirà un aggiornamento generale sull'azienda. Una registrazione sarà disponibile fino al 14 agosto 2024. Questo evento offre agli investitori l'opportunità di ottenere approfondimenti sulle performance finanziarie di ChromaDex e sulle prospettive future.
ChromaDex Corp. (NASDAQ:CDXC), un líder en investigación de NAD+ y envejecimiento saludable, ha anunciado su conferencia telefónica sobre resultados financieros del Q2 2024. La llamada está programada para miércoles 7 de agosto de 2024, a las 4:30 p.m. ET. Los resultados financieros se anunciarán a través de un comunicado de prensa después del cierre del mercado ese mismo día. Los inversores pueden unirse a la llamada utilizando el número gratuito 1-888-596-4144 (ID de Conferencia: 8584242) o a través de webcast. La gerencia discutirá los resultados del Q2 y proporcionará una actualización general del negocio. Una repetición estará disponible hasta el 14 de agosto de 2024. Este evento ofrece a los inversores la oportunidad de obtener información sobre el rendimiento financiero de ChromaDex y sus perspectivas futuras.
ChromaDex Corp. (NASDAQ:CDXC)는 NAD+ 연구 및 건강한 노화의 선두주자로서 2024년 2분기 재무 결과에 대한 전화 회의를 발표했습니다. 이 회의는 2024년 8월 7일 수요일, 오후 4시 30분 ET로 예정되어 있습니다. 재무 결과는 같은 날 시장 종료 후 보도 자료를 통해 발표됩니다. 투자자들은 수신자 부담 번호 1-888-596-4144 (회의 ID: 8584242)로 전화를 통해 또는 웹캐스트를 통해 회의에 참여할 수 있습니다. 경영진은 2분기 결과를 논의하고 사업에 대한 전반적인 업데이트를 제공합니다. 기록된 내용은 2024년 8월 14일까지 이용할 수 있습니다. 이 이벤트는 투자자들에게 ChromaDex의 재무 성과와 향후 전망에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
ChromaDex Corp. (NASDAQ:CDXC), un leader dans la recherche sur le NAD+ et le vieillissement sain, a annoncé sa conférence téléphonique sur les résultats financiers du T2 2024. L'appel est prévu pour mercredi 7 août 2024, à 16h30 ET. Les résultats financiers seront publiés via un communiqué de presse après la fermeture du marché le même jour. Les investisseurs peuvent rejoindre l'appel en utilisant le numéro sans frais 1-888-596-4144 (ID de conférence : 8584242) ou via webcast. La direction discutera des résultats du T2 et fournira une mise à jour générale sur l'entreprise. Un replay sera disponible jusqu'au 14 août 2024. Cet événement offre aux investisseurs l'occasion d'obtenir des informations sur la performance financière de ChromaDex et sur ses perspectives d'avenir.
ChromaDex Corp. (NASDAQ:CDXC), ein führendes Unternehmen in der NAD+-Forschung und gesunden Alterung, hat seine Telefonkonferenz zu den Finanzresultaten des 2. Quartals 2024 angekündigt. Die Konferenz findet am Mittwoch, den 7. August 2024, um 16:30 Uhr ET statt. Die Finanzresultate werden am selben Tag nach Börsenschluss über eine Pressemitteilung veröffentlicht. Investoren können sich über die gebührenfreie Nummer 1-888-596-4144 (Konferenz-ID: 8584242) oder über Webcast an der Konferenz beteiligen. Das Management wird die Ergebnisse des 2. Quartals besprechen und ein allgemeines Update zum Geschäft geben. Eine Aufzeichnung wird bis zum 14. August 2024 verfügbar sein. Diese Veranstaltung bietet Investoren die Möglichkeit, Einblicke in die Finanzlage von ChromaDex und die zukünftige Perspektive zu erhalten.
- None.
- None.
Investor Conference Call:
ChromaDex management will host an investor conference call to discuss the second quarter 2024 results and provide a general business update on Wednesday, August 7, at 4:30 p.m. ET. Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:
Date: Wednesday, August 7, 2024
Time: 4:30 p.m. ET (1:30 p.m. PT)
Toll-free dial-in number: 1-888-596-4144
Conference ID: 8584242
Webcast link: ChromaDex Second Quarter 2024 Earnings Conference Call
The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website at www.chromadex.com.
A replay of the conference call will be available from 7:30 p.m. EDT on August 7, 2024 to 11:59 p.m. EDT on Wednesday, August 14, 2024. The replay dial-in information is as follows:
Toll-free replay number: 1-800-770-2030
Replay ID: 8584242
For additional information on ChromaDex, visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.
Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.
Niagen® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in
ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.
†Based on the top-selling dietary supplement brands by revenue per the largest
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724562405/en/
ChromaDex Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
Source: ChromaDex Corporation
FAQ
When will ChromaDex (CDXC) report its Q2 2024 financial results?
What time is ChromaDex's (CDXC) Q2 2024 earnings conference call?
How can investors join ChromaDex's (CDXC) Q2 2024 earnings call?
Until when will the replay of ChromaDex's (CDXC) Q2 2024 earnings call be available?
